Pfizer Limited (India), a subsidiary of Pfizer Inc., has been a key player in India’s pharmaceutical market since 1950, headquartered in Mumbai. The company specializes in manufacturing, marketing, trading, and exporting pharmaceutical products, focusing on areas like cardiovascular health, oncology, infectious diseases, and vaccines, including the notable COVID-19 vaccine developed with BioNTech. Its manufacturing facilities, like the advanced plant in Goa, meet global quality standards for domestic and international markets. Pfizer invests heavily in R&D to innovate therapies and improve treatments while emphasizing sustainability and corporate social responsibility through healthcare access and infrastructure initiatives.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
| Promoters + | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% |
| FIIs + | 3.03% | 3.32% | 3.22% | 3.54% | 2.74% |
| DIIs + | 15.15% | 15.32% | 15.83% | 16.03% | 16.80% |
| Public + | 17.87% | 17.42% | 17.00% | 16.50% | 16.54% |
| No. of Shareholders | 1,12,456 | 1,09,214 | 1,06,098 | 98,824 | 1,05,015 |
The shareholding pattern of Pfizer Limited remained stable in terms of promoter ownership, consistently holding 63.92% from December 2023 to December 2024. Foreign Institutional Investors (FIIs) exhibited fluctuations, starting at 3.03% in December 2023, peaking at 3.54% in September 2024, and decreasing to 2.74% by December 2024. Domestic Institutional Investors (DIIs) steadily increased their stake, rising from 15.15% in December 2023 to 16.80% by December 2024. Public shareholding showed a gradual decline, reducing from 17.87% in December 2023 to 16.54% by December 2024. The number of shareholders varied, decreasing initially from 1,12,456 in December 2023 to a low of 98,824 in September 2024, before recovering to 1,05,015 by year-end. This data highlights Pfizer’s evolving investor dynamics, with institutional investors gaining prominence over the year.
Latest News on Pfizer
Pfizer recently agreed to a settlement of nearly $60 million to address allegations involving its subsidiary, Biohaven Ltd. The claims suggest that Biohaven knowingly caused the submission of false claims to Medicare by offering kickbacks to healthcare providers. This resolution underscores Pfizer’s commitment to compliance and ethical practices, reflecting its efforts to address and rectify such issues while maintaining accountability in its operations.
Below are the trading platforms that you can use to purchase Pfizer shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| February 2025 | 4,839.99 | 3,723.07 |
| March 2025 | 4,941.63 | 3,801.25 |
| April 2025 | 4,892.70 | 3,763.62 |
| May 2025 | 4,750.20 | 3,654.00 |
| June 2025 | 4,963.95 | 3,818.43 |
| July 2025 | 4,866.62 | 3,743.56 |
| August 2025 | 5,017.14 | 3,859.34 |
| September 2025 | 5,077.34 | 3,905.65 |
| October 2025 | 5,209.35 | 4,007.19 |
| November 2025 | 5,339.59 | 4,107.37 |
| December 2025 | 5,579.87 | 4,292.21 |
As we progress through 2025, Pfizer’s prices are expected to exhibit steady growth. Starting in February, the range is projected at ₹3,723.07 to ₹4,839.99, gradually increasing to ₹3,801.25 to ₹4,941.63 in March. By mid-year, June prices could rise to ₹3,818.43 to ₹4,963.95, followed by steady gains in August at ₹3,859.34 to ₹5,017.14. The upward trend may continue into November with a range of ₹4,107.37 to ₹5,339.59, peaking in December between ₹4,292.21 and ₹5,579.87.
| When | Maximum Price | Minimum Price |
| January 2026 | 5,747.26 | 4,420.97 |
| February 2026 | 5,603.58 | 4,310.45 |
| March 2026 | 5,715.65 | 4,396.66 |
| April 2026 | 5,832.30 | 4,486.38 |
| May 2026 | 5,774.55 | 4,441.97 |
| June 2026 | 5,918.92 | 4,553.01 |
| July 2026 | 5,802.86 | 4,463.74 |
| August 2026 | 5,982.33 | 4,601.79 |
| September 2026 | 6,101.98 | 4,693.83 |
| October 2026 | 6,260.63 | 4,815.87 |
| November 2026 | 6,417.14 | 4,936.27 |
| December 2026 | 6,577.57 | 5,059.67 |
In 2026, Pfizer’s prices are expected to show consistent growth. In January, the range is projected to be ₹4,420.97 to ₹5,747.26, followed by February at ₹4,310.45 to ₹5,603.58. By mid-year, June prices could reach ₹4,553.01 to ₹5,918.92, and August may rise to ₹4,601.79 to ₹5,982.33. The trend continues upward into November, with a range of ₹4,936.27 to ₹6,417.14, culminating in December with prices anticipated between ₹5,059.67 and ₹6,577.57.
| When | Maximum Price | Minimum Price |
| January 2027 | 6,643.35 | 5,110.27 |
| February 2027 | 6,813.69 | 5,241.30 |
| March 2027 | 7,079.43 | 5,445.71 |
| April 2027 | 6,940.61 | 5,338.93 |
| May 2027 | 6,738.46 | 5,183.43 |
| June 2027 | 7,041.69 | 5,416.68 |
| July 2027 | 6,903.62 | 5,310.48 |
| August 2027 | 7,117.13 | 5,474.72 |
| September 2027 | 7,366.23 | 5,666.33 |
| October 2027 | 7,557.75 | 5,813.66 |
| November 2027 | 7,746.70 | 5,959.00 |
| December 2027 | 7,940.36 | 6,107.97 |
| When | Maximum Price | Minimum Price |
| January 2028 | 8,099.17 | 6,230.13 |
| February 2028 | 8,306.84 | 6,389.88 |
| March 2028 | 8,630.81 | 6,639.08 |
| April 2028 | 8,461.58 | 6,508.91 |
| May 2028 | 8,215.12 | 6,319.33 |
| June 2028 | 8,584.81 | 6,603.70 |
| July 2028 | 8,416.48 | 6,474.21 |
| August 2028 | 8,676.78 | 6,674.45 |
| September 2028 | 8,980.47 | 6,908.05 |
| October 2028 | 9,213.96 | 7,087.66 |
| November 2028 | 9,444.31 | 7,264.85 |
| December 2028 | 9,680.42 | 7,446.47 |
| When | Maximum Price | Minimum Price |
| January 2029 | 9,874.02 | 7,595.40 |
| February 2029 | 10,127.20 | 7,790.16 |
| March 2029 | 10,522.16 | 8,093.97 |
| April 2029 | 10,315.85 | 7,935.27 |
| May 2029 | 10,015.39 | 7,704.14 |
| June 2029 | 10,466.08 | 8,050.83 |
| July 2029 | 10,260.86 | 7,892.97 |
| August 2029 | 10,578.21 | 8,137.08 |
| September 2029 | 10,948.44 | 8,421.88 |
| October 2029 | 11,233.10 | 8,640.85 |
| November 2029 | 11,513.93 | 8,856.87 |
| December 2029 | 11,801.78 | 9,078.29 |
| When | Maximum Price | Minimum Price |
| January 2030 | 12,037.82 | 9,259.86 |
| February 2030 | 12,346.48 | 9,497.29 |
| March 2030 | 12,827.99 | 9,867.68 |
| April 2030 | 12,576.46 | 9,674.20 |
| May 2030 | 12,210.16 | 9,392.43 |
| June 2030 | 12,759.61 | 9,815.09 |
| July 2030 | 12,509.42 | 9,622.63 |
| August 2030 | 12,896.31 | 9,920.24 |
| September 2030 | 13,347.69 | 10,267.45 |
| October 2030 | 13,694.73 | 10,534.40 |
| November 2030 | 14,037.09 | 10,797.76 |
| December 2030 | 14,388.02 | 11,067.71 |
As we move through 2030, Pfizer’s prices are anticipated to display a steady upward trend. In January, the range is expected to be ₹9,259.86 to ₹12,037.82, followed by February at ₹9,497.29 to ₹12,346.48. By mid-year, June prices are projected between ₹9,815.09 and ₹12,759.61, and August could range from ₹9,920.24 to ₹12,896.31. As we approach the year’s end, November may see prices at ₹10,797.76 to ₹14,037.09, culminating in December with an anticipated range of ₹11,067.71 to ₹14,388.02.
Financial Condition of Pfizer
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,238 |
| Expenses + | 1,578 | 1,526 | 1,775 | 1,616 | 1,555 | 1,529 |
| Operating Profit | 574 | 712 | 836 | 809 | 638 | 709 |
| OPM % | 27% | 32% | 32% | 33% | 29% | 32% |
| Other Income + | 183 | 81 | 63 | 134 | 185 | 204 |
| Interest | 11 | 15 | 11 | 13 | 15 | 14 |
| Depreciation | 103 | 109 | 115 | 106 | 62 | 61 |
| Profit before tax | 642 | 669 | 773 | 824 | 746 | 838 |
| Tax % | 21% | 26% | 21% | 24% | 26% | |
| Net Profit + | 509 | 498 | 613 | 624 | 551 | 618 |
| EPS in Rs | 111.29 | 108.77 | 133.9 | 136.38 | 120.52 | 135.06 |
| Dividend Payout % | 297% | 32% | 26% | 51% | 29% |
Pfizer’s financial journey from March 2020 to the trailing twelve months (TTM) showcases consistent performance and adaptability in a dynamic market. Sales peaked at ₹2,611 crore in March 2022 before settling at ₹2,238 crore in TTM, reflecting the company’s ability to maintain steady revenue streams despite market challenges. Operating profits remained robust, with the OPM% consistently above 30% during most years, highlighting Pfizer’s operational efficiency and strong cost management.
The company has demonstrated resilience through fluctuations in other income, which surged to ₹204 crore in TTM, significantly higher than the ₹63 crore recorded in March 2022. Stability in interest and depreciation costs further supported profitability, with profit before tax reaching a high of ₹838 crore in TTM. This underscores Pfizer’s commitment to sustaining financial health while navigating a competitive landscape.
Net profit performance remained commendable, increasing to ₹618 crore in TTM. The EPS grew steadily, peaking at ₹135.06, reflecting value creation for shareholders. While the dividend payout ratio fluctuated, with a remarkable 297% in March 2020, it settled into a more consistent range, balancing returns to shareholders with reinvestment for future growth. Pfizer’s financial results underline its strong market presence and commitment to delivering consistent value.
FAQS
As of January 30th, 2025, the share price of Pfizer is around INR ₹4,556.
Based on various market analyses and expert opinions, the expected share price target of Pfizer by 2025 is around INR 5,579.87.
As per our analysis, Pfizer share price target for 2030 would be somewhere between ₹9,259.86 and ₹14,388.02.
ALSO READ:
- Mishra Dhatu Nigam Share Price Target 2025, 2026 to 2030
- Balu Forge Industries Share Price Target 2025, 2026 to 2030
- Alembic Pharmaceuticals Share Price Target 2025, 2026 to 2030
Conclusion
In conclusion, Pfizer’s strong financial performance, steady growth in revenue, and impressive operational efficiency position it well for future success. Despite facing challenges, the company’s commitment to ethical practices, innovation, and strategic investments in R&D ensures a positive outlook. With growing institutional support and a resilient business model, Pfizer remains a reliable player in the pharmaceutical industry, offering promising prospects for both investors and global healthcare.
What did we learn?
